Albert Cha, M.D., Ph.D.
Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and
public biopharmaceutical and medical device companies. He currently
serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), ProNAi
Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL),
AirXpanders (ASX: AXP), and several private companies.
He was an investor in Ceptaris Therapeutics (acquired by Actelion),
Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan),
Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva
Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also
involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and
Prestwick Pharmaceuticals (acquired by Biovail). Other investments
include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir
Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG
Pharmaceuticals (AMAG). Albert is also a co-founder and board member of
the annual Dermatology Summit and Dermatology Entrepreneurship
Conference. Prior to joining Vivo, Albert worked at Oracle Corporation
in pharmaceutical consulting and at the Palo Alto VA Hospital as a
Albert received his B.S. and M.S. in Electrical Engineering from
Stanford University. He subsequently completed the Medical Scientist
Training Program at UCLA School of Medicine, where he received his M.D.
and Ph.D. in Neuroscience.